These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 20146161)

  • 1. [Glycemic control and cardiovascular benefit: What do we know today?].
    Hanefeld M; Schönauer M; Forst T
    Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
    Pfützner A; Schneider CA; Forst T
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):445-59. PubMed ID: 16918264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose lowering and cardiovascular disease: what do we know and what should we do?
    Cheng AY; Leiter LA
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S25-31. PubMed ID: 20489417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glycemic control and cardiovascular benefit: what do we know today?].
    Egidi G; Popert U
    Dtsch Med Wochenschr; 2011 May; 136(19):1027; author reply 1027-8. PubMed ID: 21544796
    [No Abstract]   [Full Text] [Related]  

  • 7. Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
    Fisher M
    Int J Clin Pract; 2009 Sep; 63(9):1354-68. PubMed ID: 19691621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
    Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
    Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].
    Füchtenbusch M; Hummel M
    MMW Fortschr Med; 2008 Apr; 150(17):42-4. PubMed ID: 18510157
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
    Pfützner A; Forst T
    Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose supply and insulin demand dynamics of antidiabetic agents.
    Monte SV; Schentag JJ; Adelman MH; Paladino JA
    J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
    Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
    Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
    Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes and cardiovascular disease: the role of glycemic control.
    Cheng AY; Leiter LA
    Curr Diab Rep; 2009 Feb; 9(1):65-72. PubMed ID: 19192427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New studies, new strategies, new guidelines: so that diabetic patients will live longer].
    Aumiller J
    MMW Fortschr Med; 2005 Oct; 147(41):4-6. PubMed ID: 16270500
    [No Abstract]   [Full Text] [Related]  

  • 20. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
    Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.